老年性黃斑部病變 (AMD) :競爭情形
Age-Related Macular Degeneration: Competitive Landscape to 2026
|出版日期||內容資訊||英文 153 Pages
|老年性黃斑部病變 (AMD) :競爭情形 Age-Related Macular Degeneration: Competitive Landscape to 2026|
|出版日期: 2018年12月21日||內容資訊: 英文 153 Pages||
老年性黃斑部病變 (AMD) 治療藥市場，由大型製藥公司獨佔，儘管高價產品的專利到期，大型製藥公司的開發平台候補藥確保有利的市場佔有率。
本報告提供老年性黃斑部病變 (AMD) 治療藥調查分析，開發平台的評估，臨床實驗的評估，商業性的評估，競爭情形分析相關的系統性資訊。
The Age-Related Macular Degeneration (AMD) market has been dominated by big pharma companies and their pipeline candidates are ensuring a share of this lucrative market, in spite of patent expiries of their highly-priced products.
Age-Related macular degeneration (AMD) is one of the leading cause of vision loss among people ages 50 and over in the developed world, characterized by the deterioration or breakdown of the macula, a small area of the central retina needed for sharp central vision, gradually diminishing central vision as a result in one or both eyes.
In recent years Regeneron and Bayer became top sellers in the AMD space with their anti-VEGF, Eylea. While both Bayer and Regeneron are among the top seven industry sponsors of clinical trials in AMD, neither of these companies have an AMD drug in late stages of development (Phase IIb/ Phase III) and it is expected that they will not launch a new product by 2026.
However, Novartis is planning to launch its new anti-VEGF, brolucizumab in 2019, while Roche will compensate for its loss through the launch of faricimab, first-in-class bispecific antibody in 2024 designed for the treatment of wet AMD. The current AMD market is rather sparse, comprising of only five available drugs in the US, 5EU, and Japan and four in China. One of the marketed anti-VEGFs, Roche's Avastin (bevacizumab), is used off-label for wet AMD, mainly due to its vastly lower price-tag.
The other form of the late stage of AMD is a dry or athropic form, called geographic atrophy (GA), for which no effective treatments are available, and therefore these patients remain underserved. The AMD pipeline is strong although the attrition rate is high, particularly in dry AMD, for which all drugs have failed at the clinical stage of development.
Out of the eleven drugs in late-stage clinical development, only two are being developed for the treatment of GA: Apellis' APL-2, and Ophthotech's Zimura. The majority, about 70% of the drugs in clinical stages of development, are designed to treat wet AMD, which leaves plenty of opportunities for developers to come up with effective treatments against GA.
According to the report "Age-Related Macular Degeneration: Competitive Landscape to 2026", the AMD pipeline consists of 236 drugs spanning all stages of development. Drugs inhibiting angiogenesis remain the major focus of drug developers for wet AMD as they account for close to 40% of the pipeline.
This report provides an assessment of the pipeline, clinical, and commercial landscape of AMD. Overall, it is expected that the approval of new vascular endothelial growth factor (VEGF) inhibitors with longer efficacy duration will drive AMD market growth during the next decade; however, launching anti-VEGF biosimilars, particularly of ranibizumab, and the continued pressure from payers mandating the use of the vastly cheaper Avastin for wet AMD will curb the uptake of new anti-VEGF therapies. Additionally, two anti-complement agents for the treatment of GA will drive an increase in treated AMD cases, profoundly expanding the overall AMD market.